Fig. 2From: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainTornado diagrama. ICUR incremental cost-utility ratio, QALY Quality-Adjusted Life Years, Admin administration, PFS progression-free, PPS post-progression state, A adverse events. aICER values in a are shown as negative because they correspond to the ratio of more QALYs at lower cost (dominant), ICER values in b correspond to the third quadrant, less QALYs with less costBack to article page